COVID-19 vaccines

Summary

This tender concerns the supply of COVID-19 vaccines under a framework agreement, divided into three lots. Lot 1 covers an RNA-based vaccine for ages 12 and up, with a quantity of 25,000 doses and an option for 25,000 additional doses. Lot 2 covers a protein-based vaccine for ages 12 and up, with 25,000 doses plus an option for 25,000 doses. Lot 3 covers an RNA-based vaccine from 6 months to 12 years of age, with 800 doses. Each lot includes requirements related to quality, shelf life, packaging, and regulatory compliance; exact requirements, evidence and deadlines must be checked in the tender documents.